{"url_path":"/sec/tvrd/8-k/2026-05-08/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-08","source_url":"https://www.sec.gov/Archives/edgar/data/1346830/0001104659-26-057524-index.html","accession_number":"0001104659-26-057524","cik":"0001346830","ticker":"TVRD","issuer_name":"Tvardi Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1346830/0001104659-26-057524-index.html","primary_entity_key":"0001346830","primary_entity_name":"Tvardi Therapeutics, Inc."},"word_count":319,"has_tables":true,"body_markdown":"false\n0001346830\n\n0001346830\n\n2026-05-08\n2026-05-08\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n \n\n \n\n \n\n**UNITED STATES**\n\n**SECURITIES AND\nEXCHANGE COMMISSION**\n\n**Washington, D.C.\n20549**\n\n \n\n**FORM 8-K**\n\n \n\n**CURRENT REPORT**\n\n**Pursuant to Section 13 OR 15(d) of\nThe Securities Exchange Act of 1934**\n\n \n\nDate of Report (Date of earliest event reported)\n**May 8, 2026**\n\n \n\n**TVARDI\nTHERAPEUTICS, INC.**\n\n(Exact name of registrant as specified in its charter)\n\n \n\n**Delaware**\n \n**001-36279**\n \n**75-3175693**\n\n(State or other jurisdiction\n\nof incorporation)\n \n(Commission\n\nFile Number)\n \n(IRS Employer\n\nIdentification No.)\n\n \n \n \n \n \n\n**3 Sugar Creek Ctr. Blvd.\nSuite 525\nSugar Land, Texas**\n\n \n \n \n**77478**\n\n(Address of principal executive offices)\n \n \n \n(Zip Code)\n\n \n\nRegistrant's telephone number, including area code: **(713) 489-8654**\n\n \n\n**Not Applicable**\n\n(Former Name or Former Address, if Changed Since\nLast Report)\n\n \n\nCheck the appropriate box below if the Form 8-K filing is intended\nto simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see*General Instruction\nA.2.):\n\n \n\n¨\nWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n \n\n¨\nSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n \n\n¨\nPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n \n\n¨\nPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\n \n\nSecurities registered pursuant to Section 12(b) of\nthe Act:\n\n \n\n**Title of each class**\n**Trading\nSymbol(s)**\n**Name of each exchange on which\nregistered**\n\nCommon Stock, par value $0.001 per share\nTVRD\nThe Nasdaq Stock Market LLC\n\n \n\nIndicate by check mark whether the registrant is an emerging growth\ncompany as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities\nExchange Act of 1934 (§240.12b-2 of this chapter).\n\n \n\nEmerging\ngrowth company ¨\n\n \n\nIf\nan emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying\nwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨"}